Orionis Biosciences is an oncology therapy and immunotherapy developer to advance innovative medicines for the treatment of diseases with high unmet medical need, with a focus on oncology and immunotherapy. Recently, Orionis Biosciences announced the completion of a $55 million financing, invested by Cormorant Asset Management and Novartis Venture Fund. The funding will give Orionis the flexibility to expand its R&D operations, add to its pipeline, and advance its advanced cancer immunotherapy programs into clinical trials.
This article is reproduced from: https://www.itjuzi.com/investevent/13618007
This site is for inclusion only, and the copyright belongs to the original author.